PMV Pharmaceuticals is a precision oncology company focusing on the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild-type, p53 has the ability to eliminate cancer cells. Co.'s main product candidate, PC14586, is an orally available small molecule designed to correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The PMVP stock yearly return is shown above.
The yearly return on the PMVP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PMVP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|